You are in the accessibility menu

Please use this identifier to cite or link to this item:
Eficácia e segurança da atorvastatina no tratamento de pacientes com hipercolesterolemia primária
Other Titles: 
Safety and efficacy of atorvastatin in the treatment of patients with primary hypercholesterolemia
  • Universidade Federal da Bahia (UFBA)
  • Universidade Federal do Rio Grande do Norte (UFRN)
  • Universidade de São Paulo (USP)
  • Faculdade de Medicina do ABC (FMABC)
  • Universidade Estadual Paulista (UNESP)
  • CEPRH - Centro de Pesquisa e Assistência em Reprodução Humana
Introduction: Hypercholesterolemia is an important risk factor for cardiovascular disease, the first cause of death and third reason for hospital admissions in Brazil. The reduction of serum cholesterol levels reduces morbidity and mortality from cardiovascular disease. The present study evaluated the efficacy and safety of atorvastatin in the treatment of Brazilian patients with primary hypercholesterolemia (types IIA and IIB dyslipidemias). Patients and methods: After a 4-week wash-out period, 152 patients were treated with atorvastatin at the initial dose of 10 mg/day. According to treatment efficacy within the first 8 weeks this dose could be increased to 20 mg/day. Treatment lasted for a total of 16 weeks, and its efficacy was evaluated by the reduction of serum levels of LDL-cholesterol, total cholesterol, HDL-cholesterol, and triglycerides, as well as by the propotion of patients that achieved the target levels recommended by the National Cholesterol Education Program - Adult Treatment Panel II (NCEP ATP II) Results: The analysis of efficacy was conducted in 145 patients. Atorvastatin led to significant reductions in the levels of LDL-cholesterol after 8 and 16 weeks of treatment (P<0.001 for both comparisons). The relative reduction of such levels was 38% (P<0.001 after 8 and 16 weeks). Atorvastatin also led to significant reductions of total cholesterol and triglycerides. At the end of the study, 81% of patients achieved the target LDL-cholesterol levels recommended by NCEP ATP II. Treatment was well tolerated, and was interrupted due to creatine phosphokinase elevation in only one patient. Conclusion: Atorvastatina is efficacious and safe in the treatment of patients with primary hypercholesteromia. © Copyright Moreira Jr. Editora. Todos os direitos reservados.
Issue Date: 
Revista Brasileira de Medicina, v. 62, n. 11, p. 492-497, 2005.
Time Duration: 
  • Atorvastatin
  • Hydroxymethylglutaryl CoA reductase inhibitors
  • Hypercholesterolemia; hyperlipidemia
  • atorvastatin
  • cholesterol
  • creatine kinase
  • low density lipoprotein cholesterol
  • triacylglycerol
  • abnormally high substrate concentration in blood
  • adult
  • aged
  • cholesterol blood level
  • clinical trial
  • comparative study
  • controlled clinical trial
  • controlled study
  • creatine kinase blood level
  • dose time effect relation
  • drug dose regimen
  • drug efficacy
  • drug safety
  • drug tolerability
  • female
  • health education
  • health program
  • human
  • hypercholesterolemia
  • major clinical study
  • male
  • statistical significance
  • treatment outcome
  • triacylglycerol blood level
Access Rights: 
Acesso aberto
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.